Cardiovascular

Bone morphogenetic protein 10 and one-year outcomes after open revascularisation in symptomatic peripheral arterial disease or carotid stenosis.

Skröder S, Poci D, et al. • BMC cardiovascular disorders • 2026

PubMed 42750005 DOI 10.1186/s12872-026-06568-0
TL;DR

Higher BMP10 levels were associated with MACE and all-cause mortality after endarterectomy for symptomatic PAD or carotid stenosis, but not with new-onset atrial fibrillation, in this exploratory cohort.

Key Findings

Results

Higher BMP10 levels were associated with major adverse cardiovascular events (MACE) in unadjusted Cox regression analysis.

  • HR 1.01, 95% CI 1.00–1.03; p = 0.047
  • 26 patients experienced MACE during one-year follow-up out of 210 total patients
  • Effect estimates were similar after adjustment for age and sex
  • Model-based point estimates of one-year cumulative incidence were numerically higher at higher BMP10 concentrations, although confidence intervals were wide
Results

Higher BMP10 levels were associated with all-cause mortality in unadjusted Cox regression analysis.

  • HR 1.03, 95% CI 1.01–1.04; p < 0.001
  • 13 patients died during one-year follow-up
  • Effect estimates were similar after adjustment for age and sex
  • Model-based point estimates of one-year cumulative incidence were numerically higher at higher BMP10 concentrations for all-cause mortality
Results

Higher BMP10 levels were not associated with new-onset atrial fibrillation after endarterectomy.

  • HR 1.00, 95% CI 0.97–1.03; p = 0.80
  • 10 patients developed new-onset AF among 170 patients without AF at baseline
  • 40 patients had known preoperative AF and were excluded from the new-onset AF analysis
  • No corresponding pattern of higher cumulative incidence at higher BMP10 concentrations was observed for new-onset AF
Results

Women had higher BMP10 levels than men in this cohort.

  • 63% of the 210 enrolled patients were men
  • Women were older than men
  • BMP10 concentrations were measured using a multiplex immunoassay
  • The sex difference in BMP10 levels was noted as a descriptive finding in the cohort
Methods

The study enrolled 210 patients scheduled for endarterectomy for symptomatic peripheral arterial disease (PAD) or carotid stenosis (CS) with one-year follow-up.

  • 61% of patients underwent surgery for PAD; the remaining underwent surgery for carotid stenosis
  • 63% of participants were men
  • Clinical outcomes were obtained from medical records during one-year follow-up
  • Associations were assessed using Cox proportional hazards regression
  • The study was characterized as an exploratory cohort study

What This Means

This research suggests that a protein called bone morphogenetic protein 10 (BMP10) may serve as a marker for serious cardiovascular outcomes in patients who undergo surgery to restore blood flow in peripheral arteries or carotid arteries (the arteries supplying the brain). In a group of 210 patients followed for one year after surgery, those with higher levels of BMP10 in their blood were more likely to experience major adverse cardiovascular events (such as heart attack or stroke) or to die from any cause. The associations held up even after accounting for differences in age and sex between patients. Interestingly, higher BMP10 levels were not linked to the development of new atrial fibrillation (an irregular heart rhythm) after surgery, despite BMP10 being known to have properties related to the heart's atrial chambers. This was somewhat unexpected given the protein's biological role. Women in the study tended to have higher BMP10 levels than men and were also older on average. The authors caution that this was a relatively small exploratory study and that the findings should be considered hypothesis-generating rather than definitive. The confidence intervals around many estimates were wide, meaning there is considerable uncertainty. Larger studies will be needed to confirm whether BMP10 could be a clinically useful tool for identifying patients at higher risk of serious outcomes after vascular surgery.

Have a question about this study?

Presence or severity of Hashimoto's thyroiditis does not influence basal calcitonin levels: observations from CROHT biobank.
Journal of endocrinological investigation • 2022

HT patients of all disease stages preserve Ct production as healthy individuals and there is no need for Ct measurements...
Approach to the Patient: Safety of Growth Hormone Replacement in Children and Adolescents.
The Journal of clinical endocrinology and metabolism • 2022

rhGH therapy has been used for more than 3 decades and data are largely reassuring, yet we still have much to learn abou...
Extended Absorption of Liothyronine from Poly-Zinc-Liothyronine: Results from a Phase 1, Double-Blind, Randomized, and Controlled Study in Humans.
Thyroid : official journal of the American Thyroid Association • 2022

PZL possesses the necessary properties to achieve a much improved T3 pharmacokinetic profile, with ~30% lower Cmax that...
Lipoprotein subtypes after testosterone therapy in transmasculine adolescents.
Journal of clinical lipidology • 2022

Testosterone appears to be a major contributor to differences in lipoprotein profiles, a surrogate for cardiovascular di...
Long-term testosterone undecanoate treatment in the elderly testosterone deficient male: An observational cohort study.
Andrology • 2022

Long-acting testosterone undecanoate treatment in elderly testosterone-deficient patients required more frequent dose ad...
Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism.
Clinical endocrinology • 2022

The Society for Endocrinology commissioned a multidisciplinary guideline to provide all care providers with a comprehens...

Citation

Skr&#xf6;der S, Poci D, Smith D, Dreifaldt M, Sirsj&#xf6; A, Fengsrud E, et al.. (2026). Bone morphogenetic protein 10 and one-year outcomes after open revascularisation in symptomatic peripheral arterial disease or carotid stenosis.. BMC cardiovascular disorders. https://doi.org/10.1186/s12872-026-06568-0